Mission accomplished: £1.9m grant for cancer discovery firm

Innovate UK has awarded Mission Therapeutics a £1.9 million grant for cancer treatment

Mission Therapeutics is a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer and other diseases.

The funding from Innovate UK is for the discovery of preclinical DUB inhibitors directed at specific DUBs.

DUBs are involved in multiple cellular processes including DNA damage and cell proliferation.

Mission Theraputics has said that the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs.

 Anker Lundemose, chief executive officer, Mission Therapeutics, said: “This funding support from Innovate UK is further validation of our DUB technology platform and science.

“It will help us develop our pipeline and establish Mission Therapeutics as a World-leader in the DUB field. More importantly, it will enable us to expand our search for new solutions to treat life-threatening diseases such as cancer.”